Evidence map›Paper›PMID 31792715›Full record

Trial reportAnnals of surgical oncology2020

Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.

Pranav Murthy, Mazen S Zenati, Amr I Al Abbas, Caroline J Rieser, Nathan Bahary, Michael T Lotze, Herbert J Zeh, Amer H Zureikat, Brian A Boone

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Prognostic significance of systemic immune-inflammation index in hepatocellular carcinoma: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pranav MurthyDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-4356-5170
Mazen S ZenatiDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Amr I Al AbbasDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Caroline J RieserDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Nathan BaharyDepartment of Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Michael T LotzeDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Herbert J ZehDepartment of Surgery, University of Texas Southwestern, Dallas, TX, USA.
Amer H ZureikatDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Brian A BooneDepartment of Surgery, West Virginia University, Morgantown, WV, USA. Brian.boone@hsc.wvu.edu.

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Laura F. Gibson · 2012 to 2026
$81.0M
NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

backgroundThe systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed at diagnosis. Neoadjuvant therapy (NAT) is increasingly used in the treatment of PDAC. However, biomarkers of response are lacking. This study aimed to determine the prognostic significance of SII before and after NAT and its association with the pancreatic tumor biomarker carbohydrate-antigen 19-9 (CA 19-9).

methodsThis study retrospectively analyzed all PDAC patients treated with NAT before pancreatic resection at a single institution between 2007 and 2017. Pre- and post-NAT lab values were collected to calculate SII. Absolute pre-NAT, post-NAT, and change in SII after NAT were evaluated for their association with clinical outcomes.

resultsThe study analyzed 419 patients and found no significant correlation between pre-NAT SII and clinical outcomes. Elevated post-NAT SII was an independent, negative predictor of overall survival (OS) when assessed as a continuous variable (hazard ratio [HR], 1.0001; 95% confidence interval [CI] 1.00003-1.00014; p = 0.006). Patients with a post-NAT SII greater than 900 had a shorter median OS (31.9 vs 26.1 months; p = 0.050), and a post-NAT SII greater than 900 also was an independent negative predictor of OS (HR, 1.369; 95% CI 1.019-1.838; p = 0.037). An 80% reduction in SII independently predicted a CA 19-9 response after NAT (HR, 4.22; 95% CI 1.209-14.750; p = 0.024).

conclusionPost-treatment SII may be a useful prognostic marker in PDAC patients receiving NAT.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoadjuvant TherapyPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesSurvival RateSystemic Inflammatory Response Syndrome

Identifiers

PMID31792715
PMCPMC7879583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.